Press release
Parainfluenza Virus Infection Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | AlloVir, Ansun Biopharma, Moderna Therapeutics
Parainfluenza Virus Infection Pipeline Analysis 2025 by DelveInsight
Parainfluenza Virus Infection Overview:
The human parainfluenza virus (HPIV) is a single-stranded, negative-sense RNA virus with an outer envelope, classified under the Paramyxoviridae family. HPIV is capable of causing both upper and lower respiratory tract infections (URTI and LRTI), particularly in young children under the age of 5, older adults, and those with weakened immune systems. While it shares some similarities with the influenza virus, HPIV is a distinct virus and can be clearly differentiated from myxoviruses, such as influenza. Some shared traits include limited antigenic overlap and poor replication in embryonated eggs.
The development of HPIV-related illness involves both host immune responses and viral activity. The virus attaches and fuses to host cells through two key surface proteins: hemagglutinin-neuraminidase (HN), which binds to sialic acid residues on the surface of respiratory epithelial cells, and fusion glycoproteins (F), which help merge the viral and cellular membranes. Once inside, actin and the cytoskeleton assist in the processes of viral transcription, maturation, and the transport of viral glycoproteins to the cell surface for further replication and spread.
Download our report @ https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Parainfluenza Virus Infection Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parainfluenza Virus Infection Therapeutics Market.
Key Takeaways from the Parainfluenza Virus Infection Pipeline Report
DelveInsight's Parainfluenza Virus Infection pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Parainfluenza Virus Infection treatment.
In April 2025, researchers at the University of Pennsylvania developed a clinical-grade antiviral chewing gum aimed at reducing viral loads of certain influenza A strains and herpes simplex viruses. While this innovation primarily targets influenza and herpes viruses, it represents a novel approach in antiviral therapies that could potentially be adapted for other respiratory viruses, including parainfluenza.
In March 2025, Decoy Therapeutics Inc. announced that its antiviral drug candidates, designed using the Imp3act platform, demonstrated promising activity against multiple viruses within the paramyxoviridae family, including human parainfluenza virus 3 (hPIV3). These candidates had previously shown effectiveness against respiratory syncytial virus and hPIV3.
Key Parainfluenza Virus Infection companies such as AlloVir, Ansun Biopharma, Moderna Therapeutics, and others are evaluating new drugs for Parainfluenza Virus Infection to improve the treatment landscape.
Promising Parainfluenza Virus Infection pipeline therapies in various stages of development include Oplunofusp, and others.
Parainfluenza Virus Infection Pipeline Analysis
The Parainfluenza Virus Infection pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Parainfluenza Virus Infection Market.
Categorizes Parainfluenza Virus Infection therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Parainfluenza Virus Infection drugs under development based on:
Stage of development
Parainfluenza Virus Infection Route of administration
Target receptor
Monotherapy vs. combination therapy
Parainfluenza Virus Infection Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Parainfluenza Virus Infection Licensing agreements
Funding and investment activities supporting future Parainfluenza Virus Infection market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Parainfluenza Virus Infection Emerging Drugs
Oplunofusp: Ansun Biopharma
Parainfluenza Virus Infection Companies
There are over five major companies actively working on developing treatments for Parainfluenza Virus Infection. Among them, Ansun Biopharma has a drug candidate that has progressed to the most advanced development stage so far-Phase III clinical trials.
DelveInsight's report covers around 5+ products under different phases of Parainfluenza Virus Infection clinical trials like
Parainfluenza Virus Infection Late stage Therapies (Phase III)
Parainfluenza Virus Infection Mid-stage Therapies (Phase II)
Parainfluenza Virus Infection Early-stage Therapies (Phase I)
Parainfluenza Virus Infection Pre-clinical and Parainfluenza Virus Infection Discovery stage Therapies
Parainfluenza Virus Infection Discontinued & Inactive Therapies
Parainfluenza Virus Infection pipeline report provides the Parainfluenza Virus Infection therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Parainfluenza Virus Infection Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Parainfluenza Virus Infection Therapies and Key Parainfluenza Virus Infection Companies: Parainfluenza Virus Infection Clinical Trials and recent advancements https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Parainfluenza Virus Infection Pipeline Therapeutic Assessment
• Parainfluenza Virus Infection Assessment by Product Type
• Parainfluenza Virus Infection By Stage
• Parainfluenza Virus Infection Assessment by Route of Administration
• Parainfluenza Virus Infection Assessment by Molecule Type
Download Parainfluenza Virus Infection Sample report to know in detail about the Parainfluenza Virus Infection treatment market @ Parainfluenza Virus Infection Therapeutic Assessment https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Parainfluenza Virus Infection Current Treatment Patterns
4. Parainfluenza Virus Infection - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parainfluenza Virus Infection Late-Stage Products (Phase-III)
7. Parainfluenza Virus Infection Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parainfluenza Virus Infection Discontinued Products
13. Parainfluenza Virus Infection Product Profiles
14. Parainfluenza Virus Infection Key Companies
15. Parainfluenza Virus Infection Key Products
16. Dormant and Discontinued Products
17. Parainfluenza Virus Infection Unmet Needs
18. Parainfluenza Virus Infection Future Perspectives
19. Parainfluenza Virus Infection Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Parainfluenza Virus Infection Pipeline Reports Offerings: https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parainfluenza Virus Infection Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | AlloVir, Ansun Biopharma, Moderna Therapeutics here
News-ID: 3961285 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Parainfluenza
Parainfluenza virus infection Market: Epidemiology, Therapies, Companies, DelveI …
Parainfluenza virus infection therapies, such as DAS181, ALVR106, and others, are expected to boost the Parainfluenza virus infection Market in the upcoming years.
DelveInsight has launched a new report on "Parainfluenza virus infection - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Parainfluenza virus infection, historical and forecasted epidemiology as well as the Parainfluenza virus infection market trends in the United States, EU5 (Germany, Spain, Italy,…
Parainfluenza Virus Infection Market to Expand Significantly by 2034, States Del …
The Key Parainfluenza Virus Infection Companies in the market include - Ansun Biopharma, AlloVir, MedImmune LLC, and others.
DelveInsight's "Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology as well as the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an…
Parainfluenza Virus Infection-Market Outlook report Assessment, Growth Trends, E …
It has been observed that, the global market for Parainfluenza Virus Infection-Market would be experiencing steady growth marked in million US$ by 2025. Such advancements can be attributed to the efforts put in by prime manufacturers operating in the global Parainfluenza Virus Infection-Market during the period 2028. All such statistics and figures are carefully enclosed in a recently uploaded research report titled “Parainfluenza Virus Infection-Market Insights, Epidemiology and Market” Forecast-2028,…
What's driving the Human Parainfluenza Viruses Diagnostics Market Size ? Qiagen, …
Market Study Report recently added a new report on Global Human Parainfluenza Viruses Diagnostics Market, which is an in-depth study providing complete analysis of the industry for the period 2018 to 2023. It provides complete overview of Global Human Parainfluenza Viruses Diagnostics industry considering all the major industry trends, market dynamics and competitive scenario.
The Human Parainfluenza Viruses Diagnostics market research report provides an in-depth analysis of the business space in…
Driving Innovation: Human Parainfluenza Viruses Diagnostics Market By Key Player …
Qyresearchreports include new market research report Human Parainfluenza Viruses Diagnostics to its huge collection of research reports.
Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs.
The human…
Human Parainfluenza Viruses Diagnostics Market will reach 940 million USD in 202 …
New report published by Global Info Research which offers insights on the global Human Parainfluenza Viruses Diagnostics market.
Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs.
Click…
